Search results for "Node"

showing 10 items of 1701 documents

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differ…

2012

The 1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel clearly differentiated treatment and staging recommendations for the various gastroesophageal cancers. For locally advanced gastric cancer (>= PT3N+), the preferred treatment modality was pre- and postoperative chemotherapy. The majority of panel members would also treat T2N+ or even T2N0 tumours with a similar approach mainly because pretherapeutic staging was considered highly unreliable. It was agreed that adenocarcinoma of the gastroesophageal junction (AEG) is classified best according to Siewert et al. Preoperative radiochemotherapy (RCT) is the preferred treatment for AEG type I and II tumours. For AEG type…

OncologyCancer Researchmedicine.medical_specialtyEsophageal Neoplasmspathology/surgery/therapymedicine.medical_treatmentAdenocarcinoma; pathology/surgery/therapy Carcinoma; Squamous Cell; pathology/surgery/therapy Chemoradiotherapy; Adjuvant Chemotherapy; Adjuvant Early Detection of Cancer Esophageal Neoplasms; pathology/surgery/therapy Esophagectomy Esophagogastric Junction; pathology/surgery Gastrectomy Humans Neoadjuvant Therapy Neoplasm Staging Predictive Value of Tests Stomach Neoplasms; pathology/surgery/therapy Treatment OutcomePredictive Value of TestAdenocarcinomaSDG 3 - Good Health and Well-beingPredictive Value of TestsStomach NeoplasmsGastrectomyStomach NeoplasmInternal medicineCarcinomamedicineHumansChemotherapyGastrointestinal cancerEsophageal NeoplasmLymph nodeAdjuvantEarly Detection of CancerNeoadjuvant therapyNeoplasm Stagingpathology/surgerybusiness.industryCarcinomaCancerChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseNeoadjuvant TherapyEsophagectomyTreatment Outcomemedicine.anatomical_structureSquamous CellOncologyChemotherapy AdjuvantEsophagectomyCarcinoma Squamous CellAdenocarcinomaEsophagogastric JunctionbusinessChemoradiotherapyHuman
researchProduct

Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.

2004

Matrix metalloproteinases, in particular the gelatinases MMP-2 and MMP-9, have received great attention in recent years as putative tumour markers for clinical applications. The main reason for the observed interest is their easy detection in body fluids. Moreover, recent evidence has shown multiple functions of MMPs, rather than simply degrading ECM, which include the mobilisation of growth factors and processing of surface molecules. Several authors have reported increased levels of MMPs in a number of cancers, but clinical correlations in breast cancer are still fragmentary. Thus, the aim of the present research was to investigate the activity levels of circulating gelatinases in the ser…

OncologyCancer Researchmedicine.medical_specialtyGelatinasesmatrix metalloproteinaseReceptor ErbB-2gelatin zymographyMammary glandGelatinase ABreast NeoplasmsBiologyMatrix metalloproteinaseBreast cancerbreast cancerInternal medicineProgesterone receptormedicineBiomarkers TumorGelatinaseHumansSettore BIO/06 - Anatomia Comparata E CitologiaLymph nodeMolecular and Cellular Pathologymatrix metalloproteinasesclinic correlationsmedicine.diseasePrognosismedicine.anatomical_structureEndocrinologyOncologyMatrix Metalloproteinase 9Receptors EstrogenLymphatic MetastasisMatrix Metalloproteinase 2FemaleReceptors ProgesteroneBritish journal of cancer
researchProduct

DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective stu…

2002

Purpose: The aim of this study was to determine TP53 and NM23-H1 immunoreactivity, DNA ploidy, and S-phase fraction (SPF) in a series of 160 patients undergoing resective surgery for primary operable colorectal cancer (CRC) and to establish whether these alterations have any clinical value in predicting CRC patients' prognosis. Methods: TP53 and NM23-H1 expressions were evaluated on paraffin-embedded tissue by immunohistochemistry and DNA-ploidy and SPF on frozen tissue by flow-cytometric analysis. Results: The median follow-up time in our study group was 71 months (range 34-115 months). P53 protein expression was associated with distal tumors (P < 0.05) and DNA aneuploid tumors (P < …

OncologyCancer Researchmedicine.medical_specialtyPathologyFlow-cytometric variableTime FactorsTumor suppressor geneColorectal cancerPrognosiSettore MED/06 - Oncologia MedicaColonRectumBiologyAdenocarcinomaDisease-Free SurvivalS PhasePredictive Value of TestsInternal medicinemedicineBiomarkers TumorHumansStage (cooking)Prospective cohort studyMonomeric GTP-Binding ProteinsNeoplasm StagingTP53 expressionHematologyPloidiesGeneral MedicineDNA NeoplasmCell cycleNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseColorectal cancerAdenocarcinoma MucinousImmunohistochemistrySurvival Analysismedicine.anatomical_structureTreatment OutcomeOncologyNucleoside-Diphosphate KinaseImmunohistochemistryLymph NodesTumor Suppressor Protein p53Colorectal NeoplasmsCell DivisionTranscription FactorsJournal of cancer research and clinical oncology
researchProduct

Flow cytometric DNA analysis and lysosomal cathepsins b and l in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters an…

1995

Background. The traditional factors of locally advanced laryngeal squamous cell carcinoma (LSCC) have limited predictive value for the identification of high risk patients. Therefore, it is extremely important to define prognostic factors that identify the more aggressive types. Reliable and reproducible prognostic indicators are being investigated to help clinicians identify high risk groups and address more rational treatment. Methods. Flow cytometric DNA ploidy and S-phase fraction (SPF) measurements were performed on frozen tumor tissues from a consecutive series of 71 patients with Stage III and IV LSCC. Lysosomal cathepsin B and L activity levels were determined biochemically in match…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologybiologybusiness.industryCancermedicine.diseaseCathepsin BCathepsin Lmedicine.anatomical_structureOncologyEpidermoid carcinomaInternal medicineRelative riskmedicinebiology.proteinStage (cooking)businessLymph nodeCancer
researchProduct

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

2021

Background Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment in cancer. In this study, we evaluate the potential of miR-30b-5p as a biomarker for early diagnosis of breast cancer (BC) in tissue and plasma. Methods Expression of miR-30b-5p was determined in a series of 112 BC and 40 normal breast tissues. Circulating miR-30b-5p levels in plasma samples were determined in a discovery cohort of 38 BC patients and 40 healthy donors and in a validation cohort of 83 BC patients and 83 healthy volunteers. miR-30b-5p expression was measured by quantitative real-time PCR and receiver operating…

OncologyCancer Researchmedicine.medical_specialtydiagnosisBreast NeoplasmsBreast cancerbreast cancerPositive axillary lymph nodeInternal medicinemicroRNAmedicineBiomarkers TumorHumansStage (cooking)plasmaEarly Detection of CancerOriginal ResearchReceiver operating characteristicmicroRNAbusiness.industryCancermedicine.diseasePrognosisMicroRNAsOncologyCohortBiomarker (medicine)FemalebusinessESMO Open
researchProduct

Endometrial carcinoma with tibial bone metastasis: a case report and literature review.

2018

Endometrial cancer is the most common female genital malignancy and the seventh most common cause of death from cancer in women in Western countries. The median age of occurrence is 63 years, while...

OncologyFemale circumcisionmedicine.medical_specialtyBiopsy Fine-NeedleBone NeoplasmsMalignancyHysterectomyMetastasis03 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansTibial boneAgedNeoplasm Staging030219 obstetrics & reproductive medicineTibiabusiness.industryEndometrial cancerObstetrics and GynecologyCancermedicine.diseaseImmunohistochemistryMagnetic Resonance ImagingEndometrial NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisLymph Node ExcisionFemaleRadiotherapy AdjuvantbusinessCarcinoma EndometrioidJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
researchProduct

Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation …

2012

Little information from clinical trials is available regarding the efficacy of trastuzumab treatment in subcentimetric breast carcinomas (BCs). The aim of this study was to verify the existence of correlations between HER2 and hormone receptor status, Ki67 values, grade, histotype and node involvement in a cohort of pT1a,b BCs from an area not widely covered by screening campaigns. A total of 410 pT1a,b BC formalin-fixed paraffin-embedded samples collected from eight Sicilian Anatomo-Pathological Units (APUs) were classified according to the WHO classification and tumour grading was established. Estrogen and progesterone receptor status, Ki67 labelling index and HER2 status were available. …

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryCancerRetrospective cohort studyArticlesProgesterone Receptor StatusSettore MED/08 - Anatomia Patologicamedicine.diseaseClinical trialBreast carcinoma immunohistochemistry HER2medicine.anatomical_structureOncologyTrastuzumabInternal medicineCohortsmall size breast cancer screening campaign staging immunohistochemistrymedicineBreast carcinomabusinessLymph nodemedicine.drug
researchProduct

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO stud…

2014

Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study. Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were p…

OncologyMaleCancer ResearchAdvanced biliary tract cancerPDGFRβPhases of clinical researchHif1αKaplan-Meier Estimateurologic and male genital diseasesGastroenterologyDeoxycytidineMetastasisAntineoplastic Combined Chemotherapy Protocolsheterocyclic compoundsProspective StudiesLymph nodeAged 80 and overVascular Endothelial Growth FactorsMiddle AgedSorafenibBTCfemale genital diseases and pregnancy complicationsmedicine.anatomical_structureBiliary Tract NeoplasmsTreatment OutcomeOncologyAdenocarcinomaFemaleGallbladder NeoplasmsHand-Foot Syndromemedicine.drugSorafenibAdultNiacinamidemedicine.medical_specialtyPlaceboDisease-Free SurvivalDrug Administration ScheduleDouble-Blind MethodInternal medicinemedicineBiomarkers TumorHumansddc:610neoplasmsAgedbusiness.industryGallbladderPhenylurea Compoundsmedicine.diseaseVascular Endothelial Growth Factor Receptor-2Gemcitabinedigestive system diseasesGemcitabineChemokine CXCL12VEGFR-3VEGFR-2Bile Ducts IntrahepaticBile Duct Neoplasmsc-kitQuality of LifebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile a…

2010

[11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific…

OncologyMaleCancer Researchmedicine.medical_treatment[11C]choline-PET tomotherapy prostate relapse lymph node030218 nuclear medicine & medical imagingCholineProstate cancer0302 clinical medicineProstateCarbon RadioisotopesTomographyLymph nodeAdjuvantPelvic NeoplasmsrelapseprostateGeneral MedicineAlkylatingmedicine.anatomical_structureTreatment OutcomeLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesis[11C]choline-PETEstramustineAged; Antineoplastic Agents Alkylating; Antineoplastic Agents Hormonal; Carbon Radioisotopes; Chemotherapy Adjuvant; Choline; Estramustine; Humans; Male; Neoplasm Recurrence Local; Pelvic Neoplasms; Prostatic Neoplasms; Radiotherapy Adjuvant; Treatment Outcome; Positron-Emission Tomography; Tomography Spiral ComputedEstramustinemedicine.drugmedicine.medical_specialtyAntineoplastic Agents HormonaltomotherapyAntineoplastic AgentsTomotherapy03 medical and health sciencesInternal medicinemedicinelymphChemotherapyHumansAntineoplastic Agents AlkylatingAgedChemotherapyHormonalRadiotherapybusiness.industryProstatic Neoplasmsmedicine.diseaseRadiation therapyNeoplasm RecurrenceConcomitantPositron-Emission TomographySpiral ComputedRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessTomography Spiral Computed
researchProduct

Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases and risk factors for recurrence in a high prevalence of goiter area

2010

BACKGROUND. Papillary thyroid microcarcinoma (PTMC) is diagnosed with increasing frequency. Since risk factors for an aggressive clinical behavior have not been clearly delineated, the best therapeutic option and follow up protocol for PTMC have not been established yet, especially in case of incidental diagnosis after partial thyroidectomy for benign disease. We reviewed our series of patients with PMTC to determine risk factors for recurrence in a high prevalence of goiter area. METHODS. The medical records of all the patients who underwent total thyroidectomy (TT) with a final pathology report of PTMC between October 2002 and June 2007 were reviewed. Demographic, clinical and pathologica…

OncologyMaleGoiterendocrine system diseasesmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEPapillaryPapillary thyroid cancerRisk Factors80 and overPrevalenceMedicineChildLymph nodeThyroid cancerAged 80 and overGoiterThyroidMiddle AgedPrognosismicrocarcinoma thyroid.medicine.anatomical_structureLocalItalyLymphatic MetastasisThyroidectomyFemaleRadiologyAdultendocrine systemmedicine.medical_specialtyAdolescentInternal medicineCarcinomaHumansNeoplasm InvasivenessThyroid NeoplasmsAgedCompletion thyroidectomyChi-Square Distributionbusiness.industryAdolescent; Adult; Aged; Aged; 80 and over; Carcinoma; Papillary; Chi-Square Distribution; Child; Female; Goiter; Humans; Italy; Linear Models; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence; Local; Prevalence; Prognosis; Risk Factors; Thyroid Neoplasms; ThyroidectomyCarcinomaThyroidectomymedicine.diseaseCarcinoma PapillaryNeoplasm RecurrenceLinear ModelsLymph Node ExcisionSurgeryNeoplasm Recurrence Localbusiness
researchProduct